scientific programme
41
wednesday, 25 June 2014
S-29-003
Measuring oxidative damage to cortical
white matter in blood samples from patients
with mood disorders: Evolution of biomark-
ers in psychiatry
Trevor Young, Canada
A. Andreazza
S-29-004
Biomarkers for psychiatric disorders: Expec-
tations and problems from a clinical point
of view
Hans-Jürgen Möller, Germany
Learning Objectives:
This symposia will pro-
vide and update to delegates on progress and
difficulties in developing clinically useful bio-
markers in psychiatry.
S-30
SYMPOSIUM
15:00–17:00
Room 10
Track: Translational
Topic: Neurodegenerative disorders, incl.
Parkinson‘s Disease; Alzheimer‘s Disease;
Huntington‘s Disease; Fronto-Temporal De-
mentia; Vascular Dementia (A)
Brain-Derived Neurotrophic Factor (BDNF)
and synaptic plasticity as a drug target for
cognitive dysfunction in CNS disorders
Chair:
Pradeep Nathan, United Kingdom
Co-Chair: Liliana Minichiello, United
Kingdom
S-30-001
Molecular and cellular mechanisms of syn-
aptic plasticity: Role of BDNF
Liliana Minichiello, United Kingdom
S-30-002
BDNF, adult neurogenesis and pattern sepa-
ration in the hippocampus
Tim Bussey, United Kingdom
S-30-003
Effect of BDNF polymorphism on markeres
of synaptic activity and cognition in healthy
subjects
Pradeep Nathan, United Kingdom
S-30-004
BDNF and markers of disease progression
in Alzheimer‘s disease: Findings from the
Australian Imaging Biomarkers & Lifestyle
Flagship Study of Ageing
Paul Maruff, Australia
Learning Objectives:
This symposium will
address the question as to how brain-derived
neurotrophic factor (BDNF) and synaptic
plasticity can be used as a drug target for the
development of drugs to improve cognitive
dysfunction in CNS disorders.
EW-10
EDUCATIONAL WORKSHOP
15:00–16:30
Room 13
Optimising clinical trial designs
Chair:
Lakshmi Yatham, Canada
EW-10-001
Increasing signal detection in clinical trials:
Lessons learned
Gary Sachs, USA
EW-10-002
From biological psychiatry to stratified medi-
cine clinical trials – lessons for psychiatry
from the rest of medicine
Shitij Kapur, United Kingdom
Learning Objectives:
This workshop will in-
form delegates in the different strategies that
can be used to produce a clinical trial that
is acceptable in the modern research envi-
ronment.
CP-02
CLINICAL PERSPECTIVEs
15:00–16:30
Room 8+15
Strategies to manage treatment resistant
depression
Siegfried Kasper, Austria
Learning Objectives:
In this clinical perspec-
tive delegates will be given an insight into
managing treatment resistant depression from
a leading clinical research in that field.
